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Background: Diabetes is associated with a high risk of death due to coronary artery disease (CAD). People with
diabetes suffering from CAD are frequently treated with revascularization procedures. We aim to compare trends in
the use and outcomes of coronary revascularization procedures in diabetic and non-diabetic patients in Spain
between 2001 and 2011.
Methods: We identified all patients who had undergone coronary revascularization procedures, percutaneous
coronary interventions (PCI) and coronary artery bypass graft (CABG) surgeries, using national hospital discharge
data. Discharges were grouped by diabetes status: type 2 diabetes and no diabetes. The incidence of discharges
attributed to coronary revascularization procedures were calculated stratified by diabetes status. We calculated
length of stay and in-hospital mortality (IHM). We apply joinpoint log-linear regression to identify the years in which
changes in tendency occurred in the use of PCI and CABG in diabetic and non-diabetic patients. Multivariate analysis
was adjusted by age, sex, year and comorbidity (Charlson comorbidity index).
Results: From 2001 to 2011, 434,108 PCIs and 79,986 CABGs were performed. According to the results of the
joinpoint analysis, we found that sex and age-adjusted use of PCI increased by 31.4% per year from 2001 to 2003, by
15.9% per year from 2003 to 2006 and by 3.8% per year from 2006 to 2011 in patients with diabetes. IHM among
patients with diabetes who underwent a PCI did not change significantly over the entire study period (OR 0.99;
95% CI 0.97-1.00).
Among patients with diabetes who underwent a CABG, the sex and age-adjusted CABG incidence rate increased
by 10.4% per year from 2001 to 2003, and then decreased by 1.1% through 2011. Diabetic patients who underwent a
CABG had a 0.67 (95% CI 0.63-0.71) times lower probability of dying during hospitalization than those without diabetes.
Conclusions: The annual percent change in PCI procedures increased in diabetic and non-diabetic patients. Higher
comorbidity and the female gender are associated with a higher IHM in PCI procedures. In diabetic and non-diabetic
patients, we found a decrease in the use of CABG procedures. IHM was higher in patients without diabetes than in
those with diabetes.
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Diabetes is associated with a high risk of death due
to coronary artery disease (CAD). Current figures in-
dicate that cardiovascular events are responsible for
80% of all deaths in patients with diabetes [1]. In
Spain, 75% of patients with diabetes die primarily of
CAD [2]. Recent studies reported declines in cardio-
vascular mortality in patients with diabetes [3-6],
which has been attributed to better management of
risk factors; however, these have been less pronounced
than in those without diabetes [7].
People with diabetes represent an increasing pro-
portion of CAD patients, many of whom are treated
with revascularization procedures [8]. Approximately
25% of all coronary revascularization procedures per-
formed each year in the US are done on patients
with diabetes [9]. Coronary revascularization for pa-
tients with diabetes can be achieved using coronary
artery bypass graft (CABG) surgeries or percutaneous
coronary interventions (PCIs) [10]. While PCI is
more commonly used in patients affected by single-
vessel CAD, the best strategy for patients with ad-
vanced CAD is still debated, due to a higher repeat
revascularization rate at 1-year follow-up in patients
treated using PCI [11].
Kappetein AP et al. reported the 5-year results of
the SYNTAX trial with regard to patients with dia-
betes. Of 1800 patients in the SYNTAX trial, 452 had
diabetes. In this group of diabetic patients, 5-year
rates for major adverse cardiac and cerebrovascular
events (46 vs. 29%; P < 0.001) and repeat revasculari-
zation (35 vs. 15%; P < 0.001) were significantly higher
for PCI vs. CABG [12].
The FREEDOM Trial Investigators found that, in pa-
tients with diabetes and advanced CAD, CABG was su-
perior to PCI using first generation drug-eluting stents.
The benefit of CABG stemmed from the differences in
the rates of both AMI (p < 0.001) and death from any
cause (p = 0.049) [13].
Secular trends in the use of coronary revascularization
procedures have been examined.
In the UK, Vamos et al. found that PCI rates increased
significantly (IRR 1.01 [95% CI 1.005-1.03]) in people
with diabetes from 2004–2009, whereas CABG rates de-
clined [14]. However, there are no studies investigating
national trends in the use of coronary revascularization
procedures in people with diabetes in Spain.
In this study, we used national hospital discharge data
to describe and compare trends in the use of coronary
revascularization procedures in diabetic and non-diabetic
patients between 2001 and 2011 in Spain. In particular, we
analyzed trends in the use of CABG and PCI, patient co-
morbidities, and in-hospital outcomes such as length of
stay and in-hospital mortality.Methods
A retrospective, descriptive, epidemiological study was
conducted using the Spanish National Hospital Database
(CMBD, Conjunto Minimo Básico de Datos), which com-
piles all public and private hospital data, hence covering
more than 95% of hospital discharges [15]. The CMBD
database is managed by the Spanish Ministry of Health,
Social Services and Equality and includes patient vari-
ables (sex, date of birth), date of admittance, date of dis-
charge, up to 14 discharge diagnoses, and up to 20
procedures performed during hospitalization. The Spanish
Ministry of Health, Social Services and Equality sets re-
cording standards and performs periodic audits [15].
We selected all surgical admissions of patients who
underwent coronary revascularization procedures using
the International Classification of Diseases - Ninth
Revision, Clinical Modification (ICD-9-CM). The proced-
ure codes used were: 36.10-36.19 for CABG and 36.06;
36.07; 36.09; 00.66 for PCI.
Discharges were grouped by diabetes status as follows:
no diabetes and type 2 diabetes (ICD-9-CM codes: 250.
x0; 250.x2). Patients with type 1 diabetes were excluded
(ICD-9-MC codes: 250.x1; 250.x3).
Patients who underwent both CABG and PCI during
their hospitalization were excluded.
The outcomes of interest included the percentage of
patients who died during hospitalization, defined as in-
hospital mortality (IHM) and the mean length of hos-
pital stay (LOS).
Clinical characteristics included information on overall
comorbidity at the time of surgery, which was assessed
by computing the Charlson comorbidity index (CCI).
The index applies to 17 disease categories whose scores
are totaled to obtain an overall score for each patient
[16]. The index is subsequently categorized into three
levels: 0, no disease; 1, one or two diseases; and 2, three
or more diseases [17]. To calculate the CCI, we used 17
disease categories, excluding diabetes and AMI, as de-
scribed by Thomsen RW et al. [17].
Statistical analysis
A descriptive statistical analysis was performed. Rates
for type 2 diabetic and non-diabetic patients for each
coronary revascularization procedure were calculated in
terms of 100,000 inhabitants. We also calculated the
yearly age- and sex-specific incidence rates for diabetic
and non-diabetic patients, dividing the number of cases
per year, sex, and age group by the corresponding num-
ber of people in that population group, according to data
from the Spanish National Institute of Statistics, as re-
ported on December 31 of each year [18].
In our study, we used joinpoint log-linear regression
to identify the years in which changes in tendency oc-
curred in the use of PCI and CABG in patients with and
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percentage of change (APC) in each of the periods
delimited by the points of change. The analysis started
with the minimum number of joinpoints and tested
whether the inclusion of one or more joinpoints was sta-
tistically significant [19]. In the final model, each join-
point indicated a significant change in the tendency, and
the APC was obtained in each of the segments delimited
by the joinpoints, using the weighted least squares tech-
nique. The Joinpoint Regression Program Version 4.0.4
was used for the analysis [20].
In order to test the time trend for IHM, logistic re-
gression analyses were performed with mortality as a
binary outcome, using year of discharge, sex, age, and
CCI as independent variables. Models were generated
for diabetic and non-diabetic subjects and for the entire
population, in order to compare the IHM of those who
have the disease and those who do not. Statistical ana-
lyses were performed using Stata version 10.1 (Stata,
College Station, Texas, USA). Statistical significance was
set at p < 0.05 (2-tailed).
Ethical aspects
Data confidentiality was maintained at all times according
to Spanish legislation. Patient identifiers were deleted be-
fore the database was provided to the authors, in order to
maintain patient anonymity. It is not possible to identify
patients at individual levels, either in this article or in the
database. Given the anonymous and mandatory nature of
the dataset, it was not necessary to obtain informed con-
sent. The study protocol was approved by the ethics com-
mittee of the Universidad Rey Juan Carlos.
Results
From 2001 to 2011, a total of 514,094 admissions of pa-
tients who underwent scheduled or unscheduled coronary
revascularization procedures were recorded in Spain. Over
the study period, 29.8% (n = 153,242) of all patients who
underwent coronary revascularization procedures had type
2 diabetes. There were 434,108 PCIs (29.2% [n = 126,776]
in patients with type 2 diabetes) and 79,986 CABGs (33.0%
[n = 26,466] in patients with type 2 diabetes).
Percutaneous coronary intervention
In patients who underwent a PCI, there was a significant
male predominance in patients both with and without
diabetes (69.5% and 79.9%). Mean age was 67.5 years (SD,
10.1 years) in patients with type 2 diabetes and 63.9 years
(SD, 12.1 years) in those without diabetes (p < 0.01).
Patients with type 2 diabetes who underwent PCIs had
higher CCI values compared to those without diabetes
(37.2% vs. 27.1% with one or more coexisting conditions,
respectively).Among those who received a PCI, the median LOS
was significantly higher in patients with type 2 diabetes
(6.0 days [IQR 11.0 days]) compared to those without
diabetes (5.0 days [IQR 7.0 days]). Also, IHM was signifi-
cantly higher in patients with type 2 diabetes (2.5%)
compared to patients without diabetes (2.0%).
According to the results of the joinpoint analysis, we
found that sex and age-adjusted use of PCI increased by
31.4% per year from 2001 to 2003, by 15.9% per year
from 2003 to 2006 and by 3.8% per year from 2006 to
2011 in patients with type 2 diabetes (Figure 1). In pa-
tients without diabetes, the use of PCI increased by
12.1% per year from 2001 to 2005 and by 3.6% per year
from 2005 to 2009. From 2009 to 2011, it decreased by
1.39% per year, but not significantly (Figure 2).
Table 1 shows time trend outcomes in annual PCIs
in patients with and without type 2 diabetes in Spain,
2001–2011. We found that the mean age of patients
with diabetes who underwent a PCI was 66.1 ± 9.7 years in
2001 and increased to 68.2 ± 10.4 years in 2011 (P < 0.05),
the proportion of men varied significantly from 67.1% in
2001 to 71.3% in 2011 and the prevalence of those with a
CCI of one or more increased from 30.5% in 2001 to 41.1
(P < 0.05).
LOS after PCI decreased significantly over the study
period in both groups of patients (P < 0.01), showing higher
values among those with type 2 diabetes in all years ana-
lyzed (Table 1).
The IHM among those who underwent a PCI in-
creased for those without diabetes (1.9% in 2001 vs. 2.3%
in 2011; P < 0.05) but remained stable for those suffering
from type 2 diabetes (1.9% vs. 2.5%, P = 0.10) (Table 1).
As can been seen in Table 2, after multivariate adjust-
ment, the IHM among patients with diabetes who
underwent a PCI did not change significantly from 2001 to
2011 (OR 0.99; 95% CI 0.97-1.00). IHM was significantly
higher in women than in men (OR 1.36; 95% CI 1.26-1.46)
and was higher in those with one or two (OR 2.92; 95% CI
2.71-3.15) or three or more (OR 5.27; 95% CI 4.51-6.15)
comorbidities associated with type 2 diabetes.
Coronary artery bypass graft
We found that, in patients who underwent a CABG, the
mean age was significantly higher in patients with type 2
diabetes than in those without diabetes (67.3 years [SD
8.7 years] vs. 66.4 years [SD 10.1 years]) and there was
higher proportion of males undergoing CABG procedures
in both groups (73.3% in patients with type 2 diabetes vs.
80.3% in patients without diabetes, P < 0.05).
In our study, patients with diabetes who underwent a
CABG had higher CCI values than those without dia-
betes (40.8% vs. 36.3% with one or more comorbidities).
In patients with type 2 diabetes, the IHM was signifi-
cantly lower than in those without diabetes (5.8% vs.
Figure 1 Joinpoint analysis in annual PCI in patients with type 2 diabetes in Spain, 2001–2011. Footnote: APC: Annual percent change
(based on rates that were sex and aged-adjusted using the Spanish National Statistics Institute Census projections) calculated by using joinpoint
regression analysis. ˆAPC is significantly different from zero (two-side P < 0.05).
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patients with type 2 diabetes (16 days [IQR 16 days] com-
pared with those without diabetes (15 days [IQR 15 days]).
Among patients with type 2 diabetes who underwent
CABG, the sex and age-adjusted CABG incidence rate
increased by 10.4% per year from 2001 to 2003, then de-
creased by 1.1% through 2011 (Figure 3). In patients
without diabetes, the incidence rate decreased at a con-
stant rate of 3.94% per year over the entire period of
study (Figure 4).Figure 2 Joinpoint analysis in annual PCI in patients without type 2 d
(based on rates that were sex and aged-adjusted using the Spanish Nation
regression analysis. ˆAPC is significantly different from zero (two-side P < 0.0As can be seen in Table 3, over the 11-year study
period, the mean age of patients with type 2 diabetes
who underwent CABG was 66.1 ± 8.6 years in 2001
and 67.8 ± 8.7 years in 2011. Significant differences
in age were observed (P < 0.01). In 2001 the propor-
tion of men was 70.8%, which rose to 76.4% in 2011
(P < 0.05).
In our study, LOS in patients with type 2 diabetes de-
creased significantly from 18 days (IQR, 17 days) in
2001 to 14 days (IQR, 14 days) in 2011. In patientsiabetes in Spain, 2001–2011. Footnote: APC: Annual percent change
al Statistics Institute Census projections) calculated by using joinpoint
5).
Table 1 Characteristics and outcomes of hospital discharges after percutaneous coronary intervention among patients
with and without type 2 diabetes in Spain, 2001–2011
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
No diabetes
N 16200 18842 21438 24375 27745 29184 31607 33452 34840 34463 35186
Incidence* 71.3 82.1 91.4 101.8 113.5 116.8 123.8 128.4 131.4 128.2 128.9
Age§, mean 62.9 63.0 62.8 63.3 63.7 63.9 64.1 64.3 64.4 64.3 64.5
(SD) (11.4) (11.6) (11.7) (11.7) (11.8) (11.9) (12.0) (12.2) (12.3) (12.4) (12.5)
Female ǂ, n 3039 3526 3971 4771 5542 5866 6353 6820 7199 7097 7389
(%) (18.7) (18.7) (18.5) (19.5) (19.9) (20.1) (20.1) (20.3) (20.6) (20.5) (21)
CCI 0ǂ, n 12541 14250 16116 18102 20564 21687 22987 24070 24771 24362 24683
(%) (77.4) (75.6) (75.1) (74.2) (74.1) (74.3) (72.7) (71.9) (71.1) (70.6) (70.1)
CCI 1-2ǂ, n 3561 4473 5152 6057 6928 7204 8265 8937 9574 9538 9948
(%) (21.9) (23.7) (24.0) (24.8) (24.9) (24.6) (26.1) (26.7) (27.4) (27.6) (28.2)
CCI≥ 3ǂ, n 98 119 170 216 253 293 355 445 495 563 55
(%) (0.6) (0.6) (0.7) (0.8) (0.9) (1.0) (1.1) (1.3) (1.4) (1.6) (1.5)
LOS§, median 6.0 6.0 6.0 6.0 6.0 6.0 5.0 5.0 5.0 5.0 5.0
(IQR) (9.0) (8.0) (8.0) (8.0) (7.0) (7.0) (7.0) (7.0) (6.0) (6.0) (6.0)
IHM ǂ, n 317 310 400 458 522 510 591 691 782 746 828
(%) (1.9) (1.6) (1.8) (1.8) (1.8) (1.7) (1.8) (2.0) (2.2) (2.1) (2.3)
Type 2 diabetes
N 4369 5847 7675 9188 11235 12276 13607 14662 15652 15807 16458
Incidence* 18.8 24.9 32.1 37.7 45.3 48.5 52.8 55.8 58.8 58.6 60.3
Age§, mean 66.1 66.5 66.5 66.8 67.0 67.4 67.7 67.9 67.8 68.2 68.2
(SD) (9.7) (9.7) (9.7) (9.8) (9.9) (9.9) (10.1) (10.2) (10.3) (10.4) (10.4)
Female ǂ, n 1440 1937 2463 2852 3454 3853 4255 4577 4618 4579 4723
(%) (32.9) (33.1) (32.0) (31.0) (30.7) (31.3) (31.2) (31.2) (29.5) (28.9) (28.7)
CCI 0ǂ, n 3034 3962 5040 5971 7266 8152 8586 8871 9405 9443 9691
(%) (69.4) (67.7) (65.6) (64.9) (64.6) (66.4) (63.1) (60.5) (60.0) (59.7) (58.8)
CCI 1-2ǂ, n 1284 1805 2514 3067 3755 3916 4745 5428 5846 5915 6308
(%) (29.3) (30.8) (32.7) (33.3) (33.4) (31.9) (34.8) (37.0) (37.3) (37.4) (38.3)
CCI≥ 3ǂ, n 51 80 121 150 214 208 276 363 401 449 459
(%) (1.1) (1.3) (1.5) (1.6) (1.9) (1.6) (2.0) (2.4) (2.5) (2.8) (2.7)
LOS§, median 7.0 7.0 7.0 7.0 7.0 6.0 6.0 6.0 6.0 6.0 6.0
(IQR) (10.0) (10.0) (9.0) (9.0) (8.0) (8.0) (7.0) (7.0) (7.0) (7.0) (6.0)
IHM ǂ, n 85 157 186 201 289 314 332 403 405 419 425
(%) (1.9) (2.6) (2.4) (2.1) (2.5) (2.5) (2.4) (2.7) (2.5) (2.6) (2.5)
N: Number of procedures; LOS: length of stay; IHM: In-hospital mortality;
CCI (Charlson Comorbidity Index): Comorbidities included in the Charlson comorbidity index, except diabetes and AMI.
Incidence per 100.000. Incidence was calculated using the Spanish National Statistics Institute census projections adjusted by sex and age (16).
*P < 0.05 (Poisson regression analysis).
§P < 0.05 (ANOVA or Kruskal-Wallis analysis).
ǂP < 0.05(χ2 linear tend analysis).
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the period of study (Table 3).
The IHM decreased significantly for those with and
without diabetes during the 11-year study period (7.1%
in 2001 vs. 4.4% in 2011 and 9.5% vs. 6.7%, respectively)
(Table 3).
After multivariate adjustment, the IHM among patients
with type 2 diabetes who underwent a CABG decreasedsignificantly over the entire study period (OR 0.93; 95% CI
0.91-0.94), was significantly higher in women than in men
(OR 1.69; 95% CI 1.52-1.89) and in those with one or two
(OR 2.58; 95% CI 2.31-2.88) and with three or more (OR
4.95; 95% CI 3.83-6.42) comorbidities. Patients suffering
from type 2 diabetes who underwent a CABG had a 0.67
(95% CI 0.63-0.71) times lower probability of dying during
hospitalization than those without diabetes (Table 2).
Table 2 Multivariate analysis of the factors associated with in-hospital mortality after coronary revascularization
procedures among patients with and without type 2 diabetes in Spain, 2001-2011
In-hospital mortality (OR)† In-hospital mortality (OR)† In-hospital mortality (OR)†
Type 2 diabetes No diabetes All
PCI CABG PCI CABG PCI CABG
Age (years)
35-59 1 1 1 1 1 1
60-69
1.49 1.65 1.45 1.47 1.46 1.50
(1.30-1.70) (1.35-2.01) (1.33-1.58) (1.31-1.63) (1.36-1.57) (1.37-1.65)
70-79
2.38 2.69 2.30 2.33 2.34 2.40
(2.10-2.71) (2.23-3.25) (2.14-2.48) (2.10-2.57) (2.19-2.49) (2.20-2.63)
≥80
3.73 3.55 3.93 3.42 3.88 3.44
(3.25-4.29) (2.72-4.62) (3.62-4.28) (2.99-3.91) (3.61-4.16) (3.05-3.88)
Sex
Men 1 1 1 1 1 1
Female
1.36 1.69 1.34 1.53 1.35 1.58
(1.26-1.46) (1.52-1.89) (1.26-1.42) (1.42-1.65) (1.29-1.41 (1.49-1.68)
Charlson index
0 1 1 1 1 1 1
1-2
2.92 2.58 3.14 2.56 3.07 2.56
(2.71-3.15) (2.31-2.88) (2.98-3.31) (2.40-2.74) (2.94-3.21) (2.42-2.72)
≥3
5.27 4.95 6.62 5.43 6.07 5.27
(4.51-6.15) (3.83-6.42) (5.86-7.48) (4.62-6.38) (5.51-6.68) (4.60-6.05)
Diabetes
No - - - - 1 1
Yes
- - - - 0.99 0.67
- - - - (0.95-1.04) (0.63-0.71)
Year
0.99 0.93 1.00 0.95 0.99 0.94
(0.97-1.00) (0.91-0.94) (0.99-1.01) (0.93-0.96) (0.98-1.01) (0.93-0.95)
†Calculate using logistic regression models: Odds Ratio (OR). The logistic regression multivariate model were built using as dependent variable”death (yes/no)” of
PCI or CABG respectively, and as independent variables year, sex, Charlson comorbidity index and age.
Figure 3 Joinpoint analysis in annual CABG in patients with type 2 diabetes in Spain, 2001–2011. Footnote: APC: Annual percent change
(based on rates that were sex and aged-adjusted using the Spanish National Statistics Institute Census projections) calculated by using joinpoint
regression analysis. ˆAPC is significantly different from zero (two-side P < 0.05).
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Figure 4 Joinpoint analysis in annual CABG in patients without type 2 diabetes in Spain, 2001–2011. Footnote: APC: Annual percent
change (based on rates that were sex and aged-adjusted using the Spanish National Statistics Institute Census projections) calculated by using
joinpoint regression analysis. ˆAPC is significantly different from zero (two-side P < 0.05).
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Using the Spanish National Hospital Database, we found
different trends over the last 11 years in the hospitaliza-
tions of subjects with and without type 2 diabetes who
underwent coronary revascularization procedures.
Our results reveal that patients with type 2 diabetes
account for 29.8% of all revascularization procedures in
Spain. We found an increase in PCI procedure rates from
2001 to 2011; and a decline in hospital admissions for
CABG in patients with type 2 diabetes from 2003 to 2011.
Our national results are consistent with other studies
indicating that PCI rates have increased significantly due
to advances in stent device technology and adjunctive
pharmacology and CABG rates have declined due to the
fact that this procedure is more invasive than PCI proce-
dures [14,21,22]. Rana et al. indicated that drug-eluting
stents were used more often in patients with severe co-
morbidities and multivessel disease [23], but a recent
study indicated that CABG in patients with diabetes and
coronary artery disease offers advantages in terms of sur-
vival [24]. Another advantage of CABG procedures is
with regard to the need for repeat revascularization.
Contini et al. concluded that only 51.3% of PCI diabetic
patients underwent “complete” revascularization, while
85.6% of CABG patients with type 2 diabetes did so [25].
We found that IHM increased over time among non-
diabetic patients after PCI. Vamos et al. observed that,
among those without diabetes from 2004–5 to 2009–10,
the percentage of patients who underwent a PCI and died
in the hospital increased from 0.9% to 1.5% (p < 0.001).
These authors suggest that this increase, despite techno-
logical advances in interventional techniques andimprovements in periprocedural care, may be attributable
to the increasing complexity of cases referred for PCI [14].
We agree with this interpretation, since in our popu-
lation the CCI was significantly worse in 2001 than in
2011 (CCI ≥1; 22.5% and 29.7% respectively). Another
possible explanation is that over the study period, in the
group of patients without diabetes, there may have been
an increase in the prevalence of subjects with undiag-
nosed glucose abnormalities, and consequently,with a
higher risk of adverse cardiac effects [26,27]. Kassain
et al., 2012 concluded that the risk of major adverse car-
diovascular events following a PCI in diabetics with good
glycemic control (HBA1c ≤ 7%) was not significantly differ-
ent from that of non-diabetics (adjusted HR = 1.33;95%
CI:0.38 to 4.68, P = 0.66) [28].
In our study, the IHM remained stable over time
among diabetic patients with a PCI. The higher comor-
bidity and older age can partially explain this lack of
improvement.
Holper et al. found significant improvements in mor-
tality rates over time (9.7% in 1997–1998; 6.5% in 1999;
4.1% in 2001–2002; 5.4% in 2004 and 4.7% in 2006) in
patients with diabetes treated with oral agents after a
PCI [29].
On the other hand, Vamos et al. found significant in-
creases in IHM rates for PCI from 2004 to 2010 [14].
A recent study in United States concluded that the
mortality at 3-year follow-up after PCI, of patients
with diabetes treated with oral agents, had significantly
higher adjusted hazards of death (HR: 1.32 [95% CI: 1.29
to1.35] compared to nondiabetic patients. The authors
indicated that the mechanisms for this incremental risk
Table 3 Characteristics and outcomes of hospital discharges after coronary artery bypass graft among patients with
and without type 2 diabetes in Spain, 2001–2011
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
No diabetes
N 5487 5445 5258 5203 4728 4558 4753 4746 4492 4416 4434
Incidence* 23.6 23.2 21.9 21.2 18.9 17.9 18.3 18.0 16.8 16.3 16.2
Age§, mean 65.4 65.2 65.6 66.1 66.6 66.9 66.8 66.9 67.0 67 67.6
(SD) (9.8) (9.8) (9.9) (9.9) (9.8) (10.0) (10.0) (10.1) (10.2) (10.4) (10.3)
Female ǂ, n 1055 1038 998 1043 949 869 958 978 872 921 865
(%) (19.2) (19.0) (18.9) (20.0) (20.0) (19.0) (20.1) (20.6) (19.4) (20.8) (19.5)
CCI 0ǂ, n 3889 3813 3536 3405 2983 2830 2909 2857 2607 2626 2605
(%) (70.8) (70.0) (67.2) (65.4) (63.0) (62.0) (61.2) (60.2) (58.0) (59.4) (58.7)
CCI 1-2ǂ, n 1552 1572 1649 1714 1656 1642 1750 1801 1784 1670 1713
(%) (28.2) (28.8) (31.3) (32.9) (35.0) (36.0) (36.8) (37.9) (39.7) (37.8) (38.6)
CCI≥ 3ǂ, n 46 60 73 84 89 86 94 88 101 120 116
(%) (0.8) (1.1) (1.3) (1.6) (1.8) (1.8) (1.9) (1.8) (2.2) (2.7) (2.6)
LOS§, median 16.0 16.0 16.0 15.0 16.0 16.0 16.0 15.0 15.0 14.0 15.0
(IQR) (16.0) (15.0) (14.0) (15.0) (16.0) (13.0) (15.0) (14.0) (14.0) (12.0) (14.0)
IHM ǂ, n 526 463 442 395 361 358 374 392 312 314 300
(%) (9.5) (8.5) (8.4) (7.5) (7.6) (7.8) (7.8) (8.2) (6.9) (7.1) (6.7)
Type 2 diabetes
N 1937 2159 2473 2425 2429 2527 2393 2587 2555 2479 2502
Incidence* 8.2 9.0 10.2 9.8 9.6 9.8 9.2 9.8 9.5 9.1 9.1
Age§, mean 66.1 66.8 66.7 67.0 67.2 67.7 67.3 67.4 67.5 68.0 67.8
(SD) (8.6) (8.4) (8.4) (8.7) (8.3) (8.6) (8.8) (8.8) (8.8) (8.9) (8.7)
Female ǂ, n 566 634 743 681 695 663 598 639 640 636 589
(%) (29.2) (29.3) (30.0) (28.0) (28.6) (26.2) (24.9) (24.7) (25.0) (25.6) (23.5)
CCI 0ǂ, n 1315 1395 1549 1484 1448 1533 1371 1454 1398 1343 1362
(%) (67.8) (64.6) (62.6) (61.2) (59.6) (60.6) (57.2) (56.2) (54.7) (54.1) (54.4)
CCI 1-2ǂ, n 600 730 885 893 937 952 967 1074 1096 1064 1070
(%) (30.9) (33.8) (35.7) (36.8) (38.5) (37.6) (40.4) (41.5) (42.9) (42.9) (42.7)
CCI≥ 3ǂ, n 22 34 39 48 44 42 55 59 61 72 70
(%) (1.1) (1.5) (1.5) (1.9) (1.8) (1.6) (2.3) (2.2) (2.3) (2.9) (2.8)
LOS§, median 18.0 18.0 17.0 16.0 16.0 17.0 16.0 16.0 15.0 15.0 14.0
(IQR) (17.0) (17.0) (16.0) (16.0) (16.0) (15.0) (16.0) (15.0) (14.0) (14.0) (14.0)
IHM ǂ, n 138 172 144 149 168 160 132 135 112 118 112
(%) (7.1) (7.9) (5.8) (6.1) (6.9) (6.3) (5.5) (5.2) (4.3) (4.7) (4.4)
N: Number of procedures; LOS: length of stay; IHM: In-hospital mortality; CCI (Charlson Comorbidity Index): Comorbidities included in the Charlson comorbidity
index, except diabetes and AMI.
Incidence per 100.000. Incidence was calculated using the Spanish National Statistics Institute census projections adjusted by sex and age (16).
*P < 0.05 (Poisson regression analysis).
§P < 0.05 (ANOVA or Kruskal-Wallis analysis).
ǂP < 0.05(χ2 linear tend analysis).
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atherosclerosis, microvascular disease, a prothrombotic
state, more neointimal hyperplasia, greater vascular in-
flammation, and/or further accumulation of diabetes-
related end-organ damage and comorbidities during the
follow-up period [30].
Incomplete revascularization is frequently the final
outcome in patients with multivessel coronary diseasewho undergo PCI [25]. However, we found a signifi-
cant decline in IHM in CABG patients. Hassan et al.
(2010) explain that the greater improvement in CABG
in-hospital mortality outcome versus PCI may be at-
tributable to advanced myocardial protection tech-
niques, superior perioperative critical care, and
improved patient selection and surgical timing than in
PCI patients [31].
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IHM was higher in patients without diabetes than in
those with type 2 diabetes. In England, the IHM found
in years 2009–10 among non-diabetic patients who
underwent a CABG was 3.1% compared to 2.8% among
diabetic patients [14]. However the reasons for these dif-
ferences require further investigations with clinical data
and longer follow-up outside the hospital.
In Canada, Elbarouni B et al. found that diabetic
patients continue to experience worse outcomes, in-
cluding IHM, when compared to those without diabetes.
Paradoxically, these diabetic patients are treated with less
invasive treatments compared to their nondiabetic coun-
terparts [32]. Also in the same country, Kang et al. found
that, among subjects who had antianginal use prior to
non-ST-elevation acute coronary syndrome, the preva-
lence of diabetes was 36.5% and only 20.7% among those
not using these medications. Furthermore, patients on
chronic antianginal therapy before admission had lower
rates of catheterization during hospitalization. This lat-
ter observation may be related to the fact that this
group had significantly more comorbidities, as well as a
higher burden of coronary disease at baseline than had
been previously delineated, and might not be suited to
revascularization [33].
In our investigation, the median LOS for PCI de-
creased from 7 days in 2001 to 6 days in 2011, among
diabetic patients, and from 6 to 5 days among non-
diabetics. With regard to CABG, the median was 18 days
in 2001 and 14 days in 2011 for those suffering from dia-
betes, with equivalent figures of 16 and 15 days for those
without the disease. It is remarkable that these figures
are almost twice those reported by Vamos et al., in
England, who found a median of 2 days for PCI and
9 days for CABG among those with and without diabetes
in the 2009–10 period [14].
In Spain and in England, the medical insurance
systems are very similar in terms of universal cover-
age, being funded by taxes and predominantly oper-
ating within the public sector [34,35]. Thus, we
think these large differences may be explained by
several reasons. First, the differences in the percent-
age of scheduled/emergency procedures between the
two countries; with a much higher percentage of
scheduled procedures in England. Second, the LOS
in our investigation was calculated from the time
the patient was admitted to the hospital and not
from the time that the procedure was performed.
We do not know whether the data for England was
analyzed in the same way or whether they calculated
only from the moment the procedure was performed
until the patient was discharged. Finally, the severity
of the CAD or the comorbidities was different between
the two countries.In line with the results discussed for LOS, we also
find that IHM after CABG in Spain was higher than in
England. With figures of 4.7% and 7.1% among diabetic
and non-diabetic patients in the year 2010 in Spain, and
corresponding figures for England of 2.8% and 3.1% in the
2009–10 period. These differences cannot be explained by
patient characteristics, which are similar with regard to
age and sex. Beside the aforementioned, another possible
explanation for the improvement in England is that the
prevention and treatment of cardiovascular disease and its
risk factors have assumed increasing importance in UK
health policy over the last decade; investments have been
made in health services; the introduction of a wide range
of initiatives; national treatment standards for the manage-
ment of major chronic conditions with a special focus on
secondary prevention [14,22].
In type 2 diabetes patients who had undergone either
a PCI or a CABG, women had worse outcomes than
men. Our results are consistent with those of previous
studies, which suggest that the worse effect of diabetes
on outcomes in women might be related to the onset
mechanism for cardiovascular disease, the success of the
revascularization coronary procedure, and the higher
burden of cardiovascular risk factors [21,36-38]. How-
ever, the worse results from these procedures among
women call for urgent investigations to identify and re-
duce these significant differences.
The strength of our investigation lies in its large sam-
ple size, its 11-year follow-up period and its standardized
methodology, which has previously been used to investi-
gate diabetes and its complications in Spain and else-
where [39,40]. Nevertheless, our study is subject to a
series of limitations. Our data source was the CMBD, an
administrative database that contains discharge data for
Spanish hospitalizations and uses information the phys-
ician has included in the discharge report; therefore, it
does not include all the variables of the clinical history
such as the severity of the coronary disease or other
chronic conditions, the duration of diabetes complica-
tions or treatment. Another limitation of this database is
its anonymity (no identifying items such as clinical history
number), which makes it impossible to detect whether the
same patient was admitted more than once during the
same year. In addition, patients who moved from one hos-
pital to another would appear twice.
Nevertheless, this dataset, which was introduced in
Spain in 1982, is a mandatory register, and its coverage
is estimated to be greater than 95% [15]. We were unable
to calculate diabetes-specific incidence rates, because no
studies in Spain cover blood glucose measurements or
HbA1C for the entire population; consequently, no pre-
cise estimate of the prevalence of diabetes is available
[41]. Concerns have been raised about the accuracy of
routinely-collected datasets; however, these datasets are
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ity of our dataset has been assessed and shown to be use-
ful for health research [42].
Another limitation of our study is the missing causal
relationship between IHM and CAGD/PCI as cancer
and non-cardiovascular admitted patients were also in-
cluded, the mortality of whom may not have been affected
by the CABG/PCI.Conclusions
Our results show that the annual percentage change in
PCI procedures increased in diabetic and non-diabetic
patients. Outcomes such as LOS is worse among indi-
viduals with diabetes than those without diabetes for
PCI although they improved over the entire study period
for both groups. Higher comorbidity and female gender
are associated with higher IHM in PCI procedures.
We found a decrease in the use of CABG procedures
in patients with and without type 2 diabetes. IHM was
higher in patients without type 2 diabetes than those
with it.
Given the rapid increase in the prevalence of diabetes
and the aging population, these findings emphasize the
need for further improvement in the control of cardio-
vascular risk factors in people with diabetes.
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